Comparison of Dabigatran Plus a P2Y12 Inhibitor With Warfarin-Based Triple Therapy Across Body Mass Index in RE-DUAL PCI
-
Published:2020-11
Issue:11
Volume:133
Page:1302-1312
-
ISSN:0002-9343
-
Container-title:The American Journal of Medicine
-
language:en
-
Short-container-title:The American Journal of Medicine
Author:
De Caterina RaffaeleORCID,
Procopio AntonioORCID,
Lopez Sendon José-Luis,
Raev Dimitar,
Mehta Shamir R.,
Opolski Grzegorz,
Oldgren Jonas,
Steg Philippe Gabriel,
Hohnloser Stefan H.ORCID,
Lip Gregory Y.H.ORCID,
Kimura Takeshi,
Kleine EvaORCID,
ten Berg Jurriën M.,
Bhatt Deepak L.ORCID,
Miede Corinna,
Nordaby MatiasORCID,
Cannon Christopher P.ORCID
Reference20 articles.
1. Stroke prevention in atrial fibrillation: past, present and future. Comparing the guidelines and practical decision-making;Lip;Thromb Haemost,2017
2. NOACs for treatment of venous thromboembolism in clinical practice;Schulman;Thromb Haemost,2017
3. Dabigatran/dabigatran etexilate;Sorbera;Drugs Fut,2005
4. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor;Kubitza;Clin Pharmacol Ther,2005
5. Edoxaban: a new oral direct factor Xa inhibitor;Camm;Drugs,2011